Guozhong Capital

  • Denovo Biopharma nets nearly RMB600m in Series C round

    Precision medicine company Denovo Biopharma announced the completion of a 590 million yuan Series C round of financing on June 29.
    The round was led by Zhongjin Qide Innovative Biomedical Equity Investment Fund, with participation from existing investors Jiuyou Capital, Share Capital, CITIC Securities and Sangel Capital, as well as new investors including Yingke PE, Guozhong Capital, among other